Riluzole is a persistent-selective sodium channel inhibitor (SCI), which has a therapeutic potential to treat several neurological and psychiatric disorders. SCIs form a large and diverse group, which includes widely different modes of action. Individual SCIs may be very potent in one protocol, but ineffective in another. We have developed a method for testing the “personality” of SCIs, i.e., we assess their potency under different voltage protocols. The pattern of their relative potencies gives a characteristic fingerprint which shows correlation with specific chemical properties of molecules, and may also predict their therapeutic profile. We have identified distinct modes of action for specific groups of SCIs. Riluzole was found to have a unique “personality” type; therefore, in this study we performed a detailed analysis of its mode of action. The classic SCIs lidocaine and carbamazepine as well as the persistent-selective ranolazine were used as reference compounds. We observed a paradoxical inverse use-dependence and an apparent transient facilitation on sodium channels in the presence of riluzole (but not of other drugs) when currents were evoked by short depolarizations: in such protocols, riluzole appeared to be ineffective. On the other hand, in protocols with prolonged moderate depolarizations the drug was remarkably potent; suggesting that it strongly enhanced closed state inactivation. Recovery from fast inactivation was significantly impeded by riluzole, while recovery from slow inactivated state was - remarkably - even slightly accelerated. As a possible mechanism we propose that riluzole has an exceptionally fast binding kinetics, a high affinity for pre-open closed- and fast inactivated states, while a low affinity for slow inactivated state.
Read full abstract